Improving the Efficacy of Retinoid Therapy in Childhood Neuroblastoma

提高类视黄醇治疗儿童神经母细胞瘤的疗效

• 批准号: nhmrc : 113891
• 负责人: Prof Glenn Marshall
• 金额: $ 19.69万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2000
• 资助国家: 澳大利亚
• 起止时间: 2000-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/improving-efficacy-retinoid-childhood-neuroblastoma/81199
• 关键词: Improving; Efficacy; Retinoid; Therapy; Childhood

Cancer is still the commonest disease causing death in chilhood. Childhood neuroblastoma is a cancer of the nerve tissue which presents usually as a widely spread malignancy, which responds poorly to conventional therapy, indicating the need for novel treatment approaches. Vitamin A derivatives, or retinoids, given in addition to conventional therapy improves the cure rate for children with advanced neuroblastoma to 50%. We have shown that one likely mechanism of retinoid resistance is a deficiency of retinoic acid receptor beta, which is a necessary factor in the neuroblastoma cell for converting the retinoid anti-cancer signal into an irreversible cellular change. In this project we will define why some neuroblastoma cells express low levels of this protein and test new retinoid therapies.

癌症仍然是导致儿童死亡的最常见疾病。儿童神经母细胞瘤是一种神经组织癌，通常表现为广泛扩散的恶性肿瘤，常规治疗效果不佳，表明需要新的治疗方法。在常规治疗之外给予维生素A衍生物或类维生素A可将晚期神经母细胞瘤儿童的治愈率提高到50%。我们已经证明，类维甲酸耐药的一个可能机制是缺乏维甲酸受体，这是神经母细胞瘤细胞将类维甲酸抗癌信号转化为不可逆细胞变化的必要因素。在这个项目中，我们将确定为什么一些神经母细胞瘤细胞表达低水平的这种蛋白质，并测试新的类维甲酸疗法。